Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126759602 | 12675960 | 2 | F | 20160901 | 20160823 | 20160907 | EXP | JP-PAR PHARMACEUTICAL COMPANIES-2016SCPR015771 | PAR | KATO H., SOSA H., MORI M., KANEKO T.. CLINICAL CHARACTERISTICS OF METRONIDAZOLE-INDUCED ENCEPHALOPATHY : A REPORT OF TWO CASES AND A REVIEW OF 32 JAPANESE CASES IN THE LITERATURE. KANSENSHOGAKU ZASSHI. 2015;89(5):559-566 | 0.00 | Y | 0.00000 | 20160907 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126759602 | 12675960 | 1 | PS | METRONIDAZOLE. | METRONIDAZOLE | 1 | Oral | 1.5 G / DAY | Y | 18845 | 1.5 | G | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126759602 | 12675960 | 1 | Cholangitis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126759602 | 12675960 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126759602 | 12675960 | Aphasia | |
| 126759602 | 12675960 | Coma | |
| 126759602 | 12675960 | Hemiplegia | |
| 126759602 | 12675960 | Toxic encephalopathy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |